Drugs / Measles, mumps, and rubella vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01411241 Background | Jul 2011 → Feb 2014 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Measles, mumps, and rubella vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01411241 ↗ |
| Modality | Vaccine | “a MMR vaccine” NCT01411241 ↗ |
| Route | Subcutaneous | “0.5 mL, subcutaneous” NCT01411241 ↗ |